Literature DB >> 17370102

alpha 2 beta adrenoreceptor 301-303 deletion polymorphism in polycystic ovary syndrome.

Alexandros D Saltamavros1, George Adonakis, Sosanna Kritikou, Vasiliki Koika, Kleanthis Koufogiannis, Kostas Spyropoulos, George Kourounis, Christodoulos Flordellis, Venetsana Kyriazopoulou, Neoklis A Georgopoulos.   

Abstract

alpha(2beta) adrenoreceptor 301-303 deletion polymorphism does not influence basal metabolic rate, insulin resistance or weight gain in Greek women with polycystic ovary syndrome.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17370102     DOI： 10.1007/s10286-007-0403-6

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN： 0959-9851            Impact factor:   4.435


  10 in total

Review 1.  The theoretical bases of indirect calorimetry: a review.

Authors:  E Ferrannini
Journal:  Metabolism       Date:  1988-03       Impact factor: 8.694

Review 2.  Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors.

Authors:  K Lakhani; G M Prelevic; A M Seifalian; W U Atiomo; P Hardiman
Journal:  J Obstet Gynaecol       Date:  2004-09       Impact factor: 1.246

3.  Reduced rate of energy expenditure as a risk factor for body-weight gain.

Authors:  E Ravussin; S Lillioja; W C Knowler; L Christin; D Freymond; W G Abbott; V Boyce; B V Howard; C Bogardus
Journal:  N Engl J Med       Date:  1988-02-25       Impact factor: 91.245

4.  Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization.

Authors:  K M Small; K M Brown; S L Forbes; S B Liggett
Journal:  J Biol Chem       Date:  2000-10-30       Impact factor: 5.157

5.  Alpha-2B adrenoceptor polymorphism and peripheral vasoconstriction.

Authors:  Pekka Talke; Claudia Stapelfeldt; Errol Lobo; Ronald Brown; Mika Scheinin; Amir Snapir
Journal:  Pharmacogenet Genomics       Date:  2005-05       Impact factor: 2.089

6.  Variation in the alpha2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo.

Authors:  Mordechai Muszkat; Daniel Kurnik; Joseph Solus; Gbenga G Sofowora; Hong-Guang Xie; Lan Jiang; Chara McMunn; Patrick Ihrie; James R Harris; Elliott P Dawson; Scott M Williams; Alastair J J Wood; C Michael Stein
Journal:  Pharmacogenet Genomics       Date:  2005-06       Impact factor: 2.089

7.  Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects.

Authors:  P Heinonen; M Koulu; U Pesonen; M K Karvonen; A Rissanen; M Laakso; R Valve; M Uusitupa; M Scheinin
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

Review 8.  Insulin resistance in patients with polycystic ovary syndrome.

Authors:  Annika K Schröder; Sascha Tauchert; Olaf Ortmann; Klaus Diedrich; Jürgen M Weiss
Journal:  Ann Med       Date:  2004       Impact factor: 4.709

9.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

10.  The alpha2B adrenergic receptor deletion/insertion polymorphism in morbid obesity.

Authors:  Gerasimos P Sykiotis; Eftihia Polyzogopoulou; Neoklis A Georgopoulos; Georgia Trakada; Kostas Spyropoulos; Fotios Kalfarentzos; Athanasios G Papavassiliou; Apostolos G Vagenakis; Christodoulos S Flordellis
Journal:  Clin Auton Res       Date:  2003-06       Impact factor: 4.435
  10 in total
  1 in total

1.  Relationship between human evolution and neurally mediated syncope disclosed by the polymorphic sites of the adrenergic receptor gene α2B-AR.

Authors:  Tomoyoshi Komiyama; Takatsugu Hirokawa; Kyoko Sato; Akira Oka; Hiroshi Kamiguchi; Eiichiro Nagata; Hiroshi Sakura; Kuniaki Otsuka; Hiroyuki Kobayashi
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.